Earlier this week, the U.S. Food and Drug Administration (FDA) approved a new oral treatment for consumers who suffer from acute migraines.
The drug, named Ubrelvy, is manufactured by Allergan and meant to be taken after symptoms of a migraine have already begun to set in. The FDA said the drug was proven to be more effective than placebos in two randomized, double-blind trials.
“The FDA is pleased to approve a novel treatment for patients suffering from migraine and will continue to work with stakeholders to promote the development of new safe and effective migraine therapies,” said FDA director Dr. Billy Dunn.
Many participants who took Ubrelvy in the drug trials reported feeling no pain or other associated migraine symptoms after two hours. Regulators said the results are promising for treating a serious health condition that affects millions of people.
“Migraine is an often disabling condition that affects an estimated 37 million people in the U.S. Ubrevly represents an important new option for the acute treatment of migraine in adults, as it is the first drug in its class approved for this indication,” said Dunn.